Neuroscience
Preliminary results from a 15-month open-label extension (OLE) study investigating RG6042 huntingtin protein (HTT) antisense oligonucleotide (ASO) in adults with manifest Huntington’s disease (HD)
Feb 27, 2020
by [Schobel SA]
Long-term safety, tolerability and biomarker effects of tominersen (most recently known as RG6042) were evaluated in participants of the 15-month open-label extension of the Phase I/IIa study. Results of this preliminary 15-month analysis will be presented.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Preparing document for printing…
0%
Receive this presentation and more content via email
Related Content
-
Also In Huntington's Disease:
Preliminary results from a 15-month open-label extension (OLE) study investigating RG6042 huntingtin protein (HTT) antisense oligonucleotide (ASO) in adults with manifest Huntington’s disease (HD)
-
Also In Oral Presentations:
AAN Presentation 2019: Update from SUNFISH part 1: Safety, tolerability and PK/PD from the dose-finding study, including exploratory efficacy data in patients with Type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916)
-
Also In Oral Presentations:
FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA)